Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Hepatocellular Carcinoma | Research

S100A family is a group of immune markers associated with poor prognosis and immune cell infiltration in hepatocellular carcinoma

Authors: Yuchen Qi, Yujing Zhang, Jianwen Li, Mengting Cai, Bo Zhang, Zhangtao Yu, Yuhang Li, Junkai Huang, Xu Chen, Yinghui Song, Sulai Liu

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Hepatocellular carcinoma (HCC) is one of the most common human cancers with poor prognosis in the world. HCC has become the second leading cause of cancer-related death in China. It is urgent to identify novel biomarker and valid target to effectively diagnose, treat or predict the prognosis of HCC. It has been reported that S100A family is closely related to cell proliferation and migration of different cancers. However, the values of S100As in HCC remain to be further analyzed.

Methods

We investigated the transcriptional and translational expression of S100As, as well as the value of this family in HCC patients from the various databases.

Results

S100A10 was most relevant to HCC.

Conclusions

The results from HCC patients’ tissues and different cells also confirmed the role of S100A10 in HCC. Furthermore, we proved that S100A10 could influenced the cell proliferation of HCC cells via ANXA2/Akt/mTOR pathway. However, it would appear that the relationship between S100A10 and HCC is complex and requires more research.
Appendix
Available only for authorised users
Literature
1.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed
2.
3.
Corrigendum to “EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma” [J Hepatol 69. (2018) 182–236]. J Hepatol 2019, 70(4):817.
4.
Kishi Y, Hasegawa K, Sugawara Y, Kokudo N. Hepatocellular carcinoma: current management and future development-improved outcomes with surgical resection. Int J Hepatol. 2011;2011:728103.CrossRefPubMedPubMedCentral
5.
Roxburgh P, Evans TRJ. Systemic therapy of hepatocellular carcinoma: are we making progress? Adv Ther. 2008;25(11):1089–104.CrossRefPubMed
6.
7.
Schäfer BW, Heizmann CW. The S100 family of EF-hand calcium-binding proteins: functions and pathology. Trends Biochem Sci. 1996;21(4):134–40.CrossRefPubMed
8.
Shiota M, Tsunoda T, Song Y, Yokomizo A, Tada Y, Oda Y, Naito S. Enhanced S100 calcium-binding protein P expression sensitizes human bladder cancer cells to cisplatin. BJU Int. 2011;107(7):1148–53.CrossRefPubMed
9.
Emberley ED, Murphy LC, Watson PH. S100 proteins and their influence on pro-survival pathways in cancer. Biochem Cell Biol. 2004;82(4):508–15.CrossRefPubMed
10.
Zhuang H, Chen X, Dong F, Zhang Z, Zhou Z, Ma Z, Huang S, Chen B, Zhang C, Hou B. Prognostic values and immune suppression of the S100A family in pancreatic cancer. J Cell Mol Med. 2021;25(6):3006–18.CrossRefPubMedPubMedCentral
11.
Zhao W, Han H-B, Zhang Z-Q. Suppression of lung cancer cell invasion and metastasis by connexin43 involves the secretion of follistatin-like 1 mediated via histone acetylation. Int J Biochem Cell Biol. 2011;43(10):1459–68.CrossRefPubMed
12.
Chen Y, Wang C, Song J, Xu R, Ruze R, Zhao Y. S100A2 is a prognostic biomarker involved in Immune Infiltration and Predict Immunotherapy Response in Pancreatic Cancer. Front Immunol. 2021;12:758004.CrossRefPubMedPubMedCentral
13.
Bydoun M, Sterea A, Liptay H, Uzans A, Huang W-Y, Rodrigues GJ, Weaver ICG, Gu H, Waisman DM. S100A10, a novel biomarker in pancreatic ductal adenocarcinoma. Mol Oncol. 2018;12(11):1895–916.CrossRefPubMedPubMedCentral
14.
Huang S, Zheng J, Huang Y, Song L, Yin Y, Ou D, He S, Chen X, Ouyang X. Impact of S100A4 Expression on Clinicopathological Characteristics and Prognosis in Pancreatic Cancer: A Meta-Analysis. Dis Markers 2016, 2016:8137378.
15.
Diklić M, Mitrović-Ajtić O, Subotički T, Djikić D, Kovačić M, Bjelica S, Beleslin-Čokić B, Tošić M, Leković D, Gotić M, et al. IL6 inhibition of inflammatory S100A8/9 proteins is NF-κB mediated in essential thrombocythemia. Cell Biochem Funct. 2020;38(4):362–72.CrossRefPubMed
16.
Kanehisa M, Furumichi M, Sato Y, Kawashima M, Ishiguro-Watanabe M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 2023;51(D1):D587–92.CrossRefPubMed
17.
18.
19.
Yang B, Tang S, Ma C, Li S-T, Shao G-C, Dang B, DeGrado WF, Dong M-Q, Wang PG, Ding S, et al. Spontaneous and specific chemical cross-linking in live cells to capture and identify protein interactions. Nat Commun. 2017;8(1):2240.CrossRefPubMedPubMedCentral
20.
Zheng S, Liu L, Xue T, Jing C, Xu X, Wu Y, Wang M, Xie X, Zhang B. Comprehensive Analysis of the prognosis and correlations with Immune Infiltration of S100 protein family members in Hepatocellular Carcinoma. Front Genet. 2021;12:648156.CrossRefPubMedPubMedCentral
21.
Li Y, Li X-Y, Li L-X, Zhou R-C, Sikong Y, Gu X, Jin B-Y, Li B, Li Y-Q, Zuo X-L. S100A10 accelerates aerobic glycolysis and malignant growth by activating mTOR-Signaling pathway in gastric Cancer. Front Cell Dev Biol. 2020;8:559486.CrossRefPubMedPubMedCentral
22.
Bharadwaj AG, Kempster E, Waisman DM. The ANXA2/S100A10 complex-regulation of the oncogenic plasminogen receptor. Biomolecules 2021, 11(12).
23.
Tekupalli R, Anand S, Ramachandregowda S, Kariyappa AS, Vadde R. Biomarkers for Hepatocellular Carcinoma-An updated review. Crit Rev Oncog. 2021;26(1):11–20.CrossRefPubMed
24.
Santamaria-Kisiel L, Rintala-Dempsey AC, Shaw GS. Calcium-dependent and -independent interactions of the S100 protein family. Biochem J. 2006;396(2):201–14.CrossRefPubMedPubMedCentral
25.
Fritz G, Botelho HM, Morozova-Roche LA, Gomes CM. Natural and amyloid self-assembly of S100 proteins: structural basis of functional diversity. FEBS J. 2010;277(22):4578–90.CrossRefPubMed
26.
Allgöwer C, Kretz A-L, von Karstedt S, Wittau M, Henne-Bruns D, Lemke J. Friend or foe: S100 proteins in Cancer. Cancers (Basel) 2020, 12(8).
27.
Salama I, Malone PS, Mihaimeed F, Jones JL. A review of the S100 proteins in cancer. Eur J Surg Oncol. 2008;34(4):357–64.CrossRefPubMed
28.
Sato K, Saiki Y, Arai K, Ishizawa K, Fukushige S, Aoki K, Abe J, Takahashi S, Sato I, Sakurada A, et al. S100A10 upregulation associates with poor prognosis in lung squamous cell carcinoma. Biochem Biophys Res Commun. 2018;505(2):466–70.CrossRefPubMed
29.
Noye TM, Lokman NA, Oehler MK, Ricciardelli C. S100A10 and Cancer hallmarks: structure, functions, and its emerging role in Ovarian Cancer. Int J Mol Sci 2018, 19(12).
30.
Liu G, Fei F, Qu J, Wang X, Zhao Y, Li Y, Zhang S. iTRAQ-based proteomic analysis of DMH-induced colorectal cancer in mice reveals the expressions of β-catenin, decorin, septin-7, and S100A10 expression in 53 cases of human hereditary polyposis colorectal cancer. Clin Transl Oncol. 2019;21(2):220–31.CrossRefPubMed
31.
Yanagi H, Watanabe T, Nishimura T, Hayashi T, Kono S, Tsuchida H, Hirata M, Kijima Y, Takao S, Okada S, et al. Upregulation of S100A10 in metastasized breast cancer stem cells. Cancer Sci. 2020;111(12):4359–70.CrossRefPubMedPubMedCentral
32.
Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell. 2006;124(2):263–6.CrossRefPubMed
33.
Lukanidin E, Sleeman JP. Building the niche: the role of the S100 proteins in metastatic growth. Semin Cancer Biol. 2012;22(3):216–25.CrossRefPubMed
34.
Shi H, Xiao L, Duan W, He H, Ma L, Da M, Duan Y, Wang Q, Wu H, Song X, et al. ANXA2 enhances the progression of hepatocellular carcinoma via remodeling the cell motility associated structures. Micron. 2016;85:26–33.CrossRefPubMed
35.
Yan X, Zhang D, Wu W, Wu S, Qian J, Hao Y, Yan F, Zhu P, Wu J, Huang G, et al. Mesenchymal stem cells promote Hepatocarcinogenesis via lncRNA-MUF Interaction with ANXA2 and miR-34a. Cancer Res. 2017;77(23):6704–16.CrossRefPubMed
36.
Lou Y, Yu Y, Xu X, Zhou S, Shen H, Fan T, Wu D, Yin J, Li G. Long non-coding RNA LUCAT1 promotes tumourigenesis by inhibiting ANXA2 phosphorylation in hepatocellular carcinoma. J Cell Mol Med. 2019;23(3):1873–84.CrossRefPubMed
Metadata
Title
S100A family is a group of immune markers associated with poor prognosis and immune cell infiltration in hepatocellular carcinoma
Authors
Yuchen Qi
Yujing Zhang
Jianwen Li
Mengting Cai
Bo Zhang
Zhangtao Yu
Yuhang Li
Junkai Huang
Xu Chen
Yinghui Song
Sulai Liu
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11127-3

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue

Study protocol

Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC)

Research

High glucose promotes the progression of colorectal cancer by activating the BMP4 signaling and inhibited by glucagon-like peptide-1 receptor agonist

Research article

PD-L1 stimulation can promote proliferation and survival of leukemic cells by influencing glucose and fatty acid metabolism in acute myeloid leukemia

Research

Dose prediction of organs at risk in patients with cervical cancer receiving brachytherapy using needle insertion based on a neural network method

Research

The potential of PARP as a therapeutic target across pediatric solid malignancies

Correction

Correction: Wilms’ tumour gene 1 (WT1) enhances non-small cell lung cancer malignancy and is inhibited by microRNA-498-5p
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits